Cytokinetics Inc (NASDAQ: CYTK), a late-stage biotech company focused on cardiovascular treatments, is reportedly exploring potential takeover options as it has garnered interest from at least one major pharmaceutical company in recent months.
Monopar Therapeutics Inc (NASDAQ: MNPR) will present data from its ongoing Phase 1b open-label, dose-escalating trial of camsirubicin in patients with advanced soft tissue sarcoma later today at the 2023 Connective Tissue Oncology Society
Zynex Inc's (NASDAQ: ZYXI) board of directors approved a program to repurchase up to $20.0 million.
The program will commence on November 1, 2023, and is scheduled to terminate earlier than November 1, 2024, or when the $20.0 million limit is reached.